Torrent Pharma share price in focus: Torrent Pharma, a leading pharma company in India, a constituent of the BSE 200, announced its financial results for the fourth quarter of FY26 on May 22. The company reported its Q4 FY26 results, with a consolidated net profit of Rs 389 crore, down 22 per cent YoY from Rs 498 crore in Q4 FY25. Despite the drop in net profit due to higher integration expenses, the company posted its highest-ever quarterly revenue at Rs 4,197 crore, a 42 per cent YoY increase.
The Board has recommended a final dividend of Rs 9 per equity share of face value of Rs 5. Following its Q4 results, the brokerages have shared their mixed stance on this pharma stock. Check out their ratings if you are planning to buy, sell, hold or add this stock.
DAM Capital Research maintains a buy call target price of Rs 4,941 based on consolidated financials (23x EV/EBITDA (FY28E). Reasons being:
Nirmal Bang on Torrent Pharma
The brokerage maintains HOLD on Torrent Pharma with a target price of Rs 4,898, valuing the company at 24x FY28E EV/EBITDA, implying 10% premium to its 5-year average multiple.
Torrent Pharma’s (TRP) 4QFY26 consolidated results came in ahead of NBIE estimates, largely aided by the consolidation of JB Pharma from 21-Jan-26; however, the standalone/base business performance remained broadly in line with estimates.
Excluding JB Pharma, Torrent delivered 16% YoY revenue growth with EBITDA margin sustained at 32.7%, supported by continued strong traction across key branded markets.
India business outperformed the IPM led by chronic therapies, Curatio scale-up and early success in semaglutide launches, while Brazil maintained healthy momentum driven by new launches and pricing actions. The US business continued to recover, aided by recent launches and improved offtake from existing products.
During the quarter, Torrent consolidated JB Pharma following the acquisition of a controlling stake, marking a key strategic milestone for the company.
The management remains optimistic on sustaining strong growth momentum across key markets, supported by semaglutide scale-up, differentiated India launches, continued Brazil traction and synergy benefits from the JB Pharma integration.
While the JB Pharma acquisition strengthens Torrent’s India franchise and medium-term growth visibility, current valuations largely factor in the near-term earnings and synergy benefits.
Morgan Stanley on Torrent Pharma
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
